SEC Form 4 · accession 0001209191-19-002826
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Laliberte
Officer — Sr. VP, Product Development
Period of report
Jan 4, 2019
Accepted (ET)
Jan 8, 2019 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 4, 2019 | A | 7,937 | — | A | 14,137 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $8.82 | Jan 4, 2019 | A | 50,000 | A | — | Jan 3, 2029 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019.
- F2Each RSU represents a contingent right to receive one share of Issuer common stock.
- F325% of the total shares subject to the option shall vest on December 31, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.